In October 2016, Imunetics was acquired by Oxford Immunotec Global PLC (Nasdaq:OXFD) in a cash and future payouts transaction. Immunetics Inc., a biotechnology company, works in the space of development of immunoassay and molecular probe kits and instruments for the diagnosis of infectious diseases. With a strong international presence, the firm's products include the Miniblotter instrument system for western blot, spoligotyping, and various multi-probe membrane assays; cell adhesion flow chamber for cell-cell interaction studies; and C6 peptide Lyme ELISA, a synthetic peptide ELISA test for Lyme disease anthrax. The company's products also include QuickELISA, a blood test for anthrax infection; and QualiCode western blot assays for diseases where diagnosis is challenging. In addition, it offers QuickELISA Anthrax-PA kit, an in vitro diagnostic test for the detection of antibodies to protective antigen of anthrax in human and animal samples; and BacTx Test for the bacterial contamination of platelets. In February of 2016, Immunetics announced the launch of its MycoDx assay for invasive fungal infections. Such infections are particularly dangerous to immunocompromised patients, including transplant recipients and those undergoing cancer therapies. MycoDx is a multiplex molecular assay developed by Immunetics that can identify 21 fungal pathogens in a whole blood sample.
